Researchers investigating incretin-based receptor pharmacology may find the following external resources useful: retatrutide triple-hormone-receptor agonist clinical trial (PMID: 37366315) and NCBI Biotechnology Information
Targeted Support: LESS CRAVING, MORE DOING - By promoting the natural production of GLP-1, GLP-1 Probiotic helps curb cravings, which can help maintain a healthy weight and empower you to take charge of your day
Feature: Targets: Semaglutide: GLP-1 Tirzepatide: GLP-1 + GIP Retatrutide: GLP-1 + GIP + Glucagon Max Weight Loss: Semaglutide: ~15% Tirzepatide: ~22% Retatrutide: 24.2%+ Energy Expenditure: Semaglutide: Low Tirzepatide: Moderate Retatrutide: High Muscle Preservation: Semaglutide: Moderate Tirzepatide: Moderate Retatrutide: Better Dosing Frequency: All: Weekly The addition of glucagon receptor activation gives Retatrutide a unique fat-burning advantage, making it ideal for visceral fat reduction and metabolic reset protocols
doi: 10.1172/JCI1349
Retatrutide is being researched for obesity, overweight with weight-related health concerns, type 2 diabetes, and other metabolic conditions
Understanding who does what helps you evaluate the platform and know exactly who is responsible for each part of your care
